Accuray Announces 1-for-40 Reverse Stock Split
ACCURAY INC (ARAY) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Accuray Announces 1-for-40 Reverse Stock Split MADISON, Wis., Nov. 4, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that its Board of Directors has approved a 1-for-40 reverse stock split of the Company’s common stock and a corresponding de
- Ratio
- 1-for-40
- Reverse split
- yes
- Effective
- November 9, 2026
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The split aims to boost share price, improve liquidity, and maintain Nasdaq listing, which could broaden the investor base.
Market read
Primary corporate action that directly affects ARAY's share structure and compliance status, offering a clear trading trigger.
What to watch
Potential dilution from future equity raises or execution risk of the split could offset price gains.
Background
Accuray (NASDAQ: ARAY) provides radiation therapy systems; its share price had fallen below Nasdaq's $1 minimum, prompting the reverse split.
Ticker impact
SEC 8‑K filing announces a 1‑for‑40 reverse stock split effective Nov 9, 2026 to regain Nasdaq minimum price compliance.
likely upward pressure as the market prices in the higher share price and compliance restoration
Reverse splits are rare and signal a firm’s effort to avoid delisting; traders often buy ahead of the split anticipating price appreciation.
Market effects
May improve perception of the medical‑technology sector by showing proactive compliance actions.
Limited to U.S. Nasdaq‑listed biotech/med‑tech stocks.
Minimal global impact beyond investors tracking Nasdaq compliance trends.
Counterpoint
Some investors may view the split as a red flag of underlying weakness and short the stock.
Key entities
- CompanyAccuray Inc.
Medical‑technology firm announcing the reverse split.
- Service ProviderComputershare Trust Company, N.A.
Acting as exchange agent for the split.
